CNSX:LXX Lexaria Bioscience (LXX) Stock Price, News & Analysis → See this before next week's Fed meeting (From Stansberry Research) (Ad) Free LXX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume48,200 shsAverage Volume250,001 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Lexaria Bioscience alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Lexaria Bioscience Stock (CNSX:LXX)Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. LXX Stock News HeadlinesApril 9, 2024 | msn.comLEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024February 22, 2024 | benzinga.comLexaria Bioscience Stock (NASDAQ:LEXXW) Dividends: History, Yield and DatesApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)January 30, 2024 | msn.comLexaria submits IND to begin Phase 1b study of DehyraTECH-CBDDecember 1, 2023 | markets.businessinsider.comBuy Rating on Lexaria Bioscience: Promising DehydraTECH Study and Market PotentialNovember 27, 2023 | msn.comLexaria stock rallies 20% on positive GLP-1 drug delivery studyJuly 22, 2023 | msn.comMaxim Group Initiates Coverage of Lexaria Bioscience (LEXX) with Buy RecommendationJune 16, 2023 | benzinga.comLexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal StudyApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)May 12, 2023 | marketwatch.comCannabisNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual MeetingMay 9, 2023 | benzinga.comLexaria Bioscience shares are trading lower after the company priced a 2.1 million unit offering at $0.95 per unit.May 9, 2023 | msn.comLexaria Bioscience prices $2.0M stock offeringMay 8, 2023 | benzinga.comLexaria's Human Clinical Nicotine Study Completes Dosing as PlannedApril 26, 2023 | finance.yahoo.comLEXX: DehydraTECH CBD May Offer New Mechanism of ActionMarch 4, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol LevelsFebruary 22, 2023 | nasdaq.comLexaria Bioscience Corp. Common Stock (LEXX)September 26, 2022 | finance.yahoo.comLexaria Bioscience Corp. (LEXX)August 31, 2022 | finance.yahoo.comLexaria Receives New Patent in MexicoAugust 12, 2022 | marketwatch.comNetworkNewsAudio - Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension TreatmentsAugust 12, 2022 | marketwatch.comCannabisNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND ProgramAugust 11, 2022 | apnews.comLexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment SolutionAugust 11, 2022 | finance.yahoo.comLexaria Discusses Valuation Metrics for Biotech IndustryAugust 10, 2022 | finance.yahoo.comLexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for HypertensionJuly 27, 2022 | msn.comLexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse EventsJune 21, 2022 | finance.yahoo.comLexaria Signs Manufacturing and License Agreements with BevNologyJune 21, 2022 | seekingalpha.comLexaria stock soars 19% on 2 manufacturing/license agreements with BevNologyJune 3, 2022 | seekingalpha.comLexaria inks licensing deal for drug delivery tech with Premier Wellness for Japanese marketSee More Headlines Receive LXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCNSX SectorConsumer Defensive Industry Packaged Foods Sub-IndustryN/A Current SymbolCNSX:LXX CUSIPN/A CIKN/A Webwww.lexariaenergy.com Phone250-765-6424FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Christopher A. Bunka (Age 57)Chairman & CEO Mr. John M. Docherty (Age 50)Pres & Director Mr. Allan Spissinger (Age 50)CFO, Corp. Sec. & Treasurer Mr. Alex BlanchardMang. Corp. Communications & Investor RelationsDr. Edward ErgenzingerChief Legal Officer & Sr. VP of InnovationKey CompetitorsEat Beyond GlobalCNSX:EATSTinley BeverageCNSX:TNYAdecoagroCNSX:AGROEmpower ClinicsCNSX:TAATNaturally Splendid EnterprisesCVE:NSPView All Competitors LXX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Lexaria Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexaria Bioscience investors own include Cross Timbers Royalty Trust (CRT), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), CRISPR Therapeutics (CRSP), KushCo (KSHB), Brigham Minerals (MNRL), Vapor Group (VPOR) and Arbor Realty Trust (ABR). How do I buy shares of Lexaria Bioscience? Shares of LXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (CNSX:LXX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyWill this $2 AI stock double overnight?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
